Truist downgraded Axonics (AXNX) to Hold from Buy with a price target of $71, down from $73, following the recent announcement of its agreement to be acquired by Boston Scientific (BSX). The firm views the deal as highly likely to close without issue, so it thinks the stock is no longer trading on fundamentals and will stay near, if not at, the proposed deal price.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXNX:
- Axonics downgraded to Equal Weight from Overweight at Wells Fargo
- NeuroPace price target raised to $17 from $12 at Lake Street
- Axonics downgraded to Peer Perform from Outperform at Wolfe Research
- Axonics downgraded to Sector Perform from Outperform at RBC Capital
- M & A News: Boston Scientific (NYSE:BSX) to Acquire Axonics in $3.7B Deal
